Compare CTSO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | ECOR |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9M | 39.6M |
| IPO Year | N/A | 2018 |
| Metric | CTSO | ECOR |
|---|---|---|
| Price | $0.70 | $4.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $25.50 |
| AVG Volume (30 Days) | ★ 119.9K | 34.3K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,979,520.00 | $29,835,000.00 |
| Revenue This Year | $9.51 | $28.61 |
| Revenue Next Year | $24.40 | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.89 | ★ 27.90 |
| 52 Week Low | $0.60 | $4.16 |
| 52 Week High | $1.61 | $19.49 |
| Indicator | CTSO | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 46.06 |
| Support Level | $0.66 | $4.78 |
| Resistance Level | $0.76 | $5.09 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 6.57 | 31.71 |
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.